Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) trades at $0.359 with AI Score 38/100 (Grade D). Nichi-Iko Pharmaceutical Co. , Ltd. is a Japanese company focused on manufacturing, selling, and distributing pharmaceutical products, particularly generic drugs. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NHKFF: NHKFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NHKFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NHKFF: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) Healthcare & Pipeline Overview
Nichi-Iko Pharmaceutical Co., Ltd., based in Japan, specializes in the production and distribution of generic drugs, operating through the Nichi-Iko Group and Sagent Group. The company provides a range of pharmaceutical products to medical institutions, addressing treatments for circulatory, digestive, respiratory, and nervous system ailments, positioning itself within the competitive generic drug market.
What Is the Investment Thesis for NHKFF?
Nichi-Iko Pharmaceutical Co., Ltd. presents a mixed investment case. The company's focus on generic drugs offers a stable revenue stream, particularly in cost-conscious healthcare markets. The low P/E ratio of 0.27 may indicate undervaluation, but the modest profit margin of 3.9% and gross margin of 19.7% suggest potential operational inefficiencies. The negative beta of -0.66 indicates low volatility relative to the market, which could appeal to risk-averse investors. Growth catalysts include expanding its generic drug portfolio and penetrating new markets. However, potential risks include regulatory challenges and competition from other generic drug manufacturers. Investors should closely monitor the company's ability to improve profitability and navigate the evolving healthcare landscape.
Based on FMP financials and quantitative analysis
NHKFF Key Highlights
P/E ratio of 0.27, potentially indicating undervaluation compared to industry peers.
- Profit margin of 3.9%, reflecting moderate profitability within the pharmaceutical sector.
- Gross margin of 19.7%, suggesting areas for potential improvement in cost management.
- Beta of -0.66, indicating lower volatility compared to the broader market, which may appeal to risk-averse investors.
- No dividend yield, meaning investors won't receive income from dividends, focusing returns on potential capital appreciation.
Who Are NHKFF's Competitors?
NHKFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.09 | -1.90% | $11.8M | 52 |
| BMKDF BioMark Diagnostics Inc. | $0.36 | -16.33% | $37.8M | 47 |
| CWBHF Charlotte's Web Holdings, Inc. | $0.31 | -2.77% | $83.1M | 51 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NHKFF's Key Strengths?
Established presence in the generic drug market.
- Diverse portfolio of pharmaceutical products.
- Supply relationships with various medical institutions.
- Operates through two segments, Nichi-Iko Group and Sagent Group.
What Are NHKFF's Weaknesses?
Modest profit margin of 3.9%.
- Gross margin of 19.7% indicates potential cost management issues.
- Reliance on generic drug manufacturing, subject to pricing pressures.
- Unknown disclosure status on OTC market.
What Could Drive NHKFF Stock Higher?
Potential new generic drug approvals could expand the product portfolio.
- Efforts to streamline manufacturing processes and reduce costs.
- Strategic acquisitions to enhance competitive advantage.
- Expansion into new geographic markets.
- Development and launch of biosimilars.
What Are the Key Risks for NHKFF?
Intense competition in the generic drug market could lead to pricing pressures.
- Regulatory challenges and compliance requirements could increase costs.
- Supply chain disruptions could impact manufacturing and distribution.
- Modest profit margin of 3.9% indicates potential operational inefficiencies.
- Trading on the OTC market involves higher risks due to limited disclosure and liquidity.
What Are the Growth Opportunities for NHKFF?
- Expanding Generic Drug Portfolio: Nichi-Iko can grow by developing and launching new generic drugs as patents expire on branded pharmaceuticals. The global generic drug market is projected to reach $459.35 billion by 2027, offering substantial opportunities for expansion. By investing in R&D and regulatory approvals, Nichi-Iko can capitalize on this growing market and increase its revenue streams over the next 3-5 years.
- Penetrating New Markets: Nichi-Iko can expand its geographic footprint by entering new markets, particularly in emerging economies with growing healthcare needs. These markets often have less stringent regulatory requirements and lower manufacturing costs, providing a competitive advantage. Successfully entering new markets could increase revenue and diversify the company's geographic risk profile within the next 2-4 years.
- Strategic Acquisitions: Nichi-Iko can pursue strategic acquisitions to expand its product portfolio, gain access to new technologies, or enter new markets. The pharmaceutical industry is consolidating, and acquisitions can provide synergies and economies of scale. Identifying and integrating suitable acquisition targets could enhance Nichi-Iko's competitive position and drive growth over the next 2-3 years.
- Focusing on Biosimilars: As more biosimilars enter the market, Nichi-Iko can invest in developing and manufacturing these complex drugs. The biosimilars market is expected to grow significantly, driven by the high cost of biologic drugs and increasing regulatory support for biosimilars. Successfully developing and launching biosimilars could provide a high-growth revenue stream over the next 5 years.
- Improving Operational Efficiency: Nichi-Iko can improve its profitability by streamlining its manufacturing processes, reducing costs, and optimizing its supply chain. Implementing lean manufacturing principles and investing in automation can enhance efficiency and reduce waste. These operational improvements can lead to higher profit margins and a stronger competitive position within the next 1-2 years.
What Are NHKFF's Competitive Advantages?
- Established presence in the Japanese generic drug market.
- Focus on manufacturing a wide range of pharmaceutical products.
- Supply relationships with numerous medical institutions.
What Does NHKFF Do?
Nichi-Iko Pharmaceutical Co., Ltd. was founded in 1947 and is headquartered in Toyama, Japan. Originally named Nihon Iyakuhin Kogyo Co., Ltd., the company changed its name in 2005 to Nichi-Iko Pharmaceutical Co., Ltd. The company operates through two primary segments: Nichi-Iko Group and Sagent Group. Nichi-Iko focuses on manufacturing, selling, and distributing a wide array of pharmaceutical products, with a strong emphasis on generic drugs. These products include antidiabetic agents, antacids, antireflux agents, beta-blockers, hypnotics and sedatives, angiotensin II antagonists, angiotensin II antagonist/diuretic combinations, dyslipidaemic agents, calcium antagonists, and chemotherapeutic agents. The company also provides treatments for circulatory, digestive, respiratory, and nervous system disorders, as well as allergies. Nichi-Iko supplies its products to various medical institutions, including hospitals, clinics, and dispensing pharmacies. The company aims to provide affordable and accessible healthcare solutions through its generic drug offerings, contributing to the overall healthcare ecosystem.
What Products and Services Does NHKFF Offer?
- Manufactures a wide range of pharmaceutical products.
- Specializes in the production of generic drugs.
- Offers treatments for circulatory, digestive, and respiratory ailments.
- Provides medications for nervous system disorders and allergies.
- Supplies products to hospitals, clinics, and pharmacies.
- Operates through the Nichi-Iko Group and Sagent Group segments.
How Does NHKFF Make Money?
- Develops and manufactures generic pharmaceutical products.
- Sells and distributes these products to medical institutions.
- Generates revenue through the sale of generic drugs and other pharmaceutical products.
What Industry Does NHKFF Operate In?
Nichi-Iko Pharmaceutical Co., Ltd. operates in the generic drug manufacturing industry, a sector characterized by intense competition and pricing pressures. The global generic drug market is driven by patent expirations of branded drugs and the increasing demand for affordable healthcare solutions. Nichi-Iko competes with other generic drug manufacturers such as AVCNF, BMKDF, CWBHF, ELIXF and GBLP. The company's success depends on its ability to efficiently manufacture and distribute generic drugs, navigate regulatory hurdles, and maintain cost competitiveness in a consolidating market.
Who Are NHKFF's Key Customers?
- Hospitals
- Clinics
- Dispensing pharmacies
- Medical institutions
Key Financial Metrics
Return on equity for Nichi-Iko Pharmaceutical Co., Ltd. stands at 12.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.6%, showing how much profit it generates from its asset base. NHKFF trades at a trailing price-to-earnings ratio of 0.27, below the Healthcare sector average of ~23x. A current ratio of 1.44 indicates the company holds enough short-term assets to cover its near-term obligations.
NHKFF Valuation & Market Position
Relative to its peer group, NHKFF's quantitative score of 38/100 is below the peer average of 59/100.
Company Profile
Nichi-Iko Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toyama, JP. The company is led by CEO Shingo Iwamoto. NHKFF has traded publicly since 2020.
NHKFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future performance.
- Community sentiment has shifted positively, with discussions highlighting potential growth in the pharmaceutical sector.
- Nichi-Iko's strong pipeline of generic drugs is appealing, suggesting robust revenue opportunities ahead.
- Market perception has improved due to increased demand for affordable medications, aligning with Nichi-Iko's offerings.
Bear Case
- Concerns persist about regulatory challenges that could impact product approvals and market entry.
- Recent bearish sentiment in online forums reflects worries about competition in the generics market.
- Analysts are cautious about the company's ability to maintain margins amid rising production costs.
- The overall market volatility in the pharmaceutical sector raises uncertainty about sustained growth for Nichi-Iko.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NHKFF Latest News
No recent news available for NHKFF.
NHKFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NHKFF.
Price Targets
Wall Street price target analysis for NHKFF.
NHKFF MoonshotScore
What does this score mean?
The MoonshotScore rates NHKFF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Shingo Iwamoto
CEO
Shingo Iwamoto is the CEO of Nichi-Iko Pharmaceutical Co., Ltd. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic management and operational efficiency. He has held various leadership positions within the company, contributing to its growth and expansion. Iwamoto's expertise lies in navigating the complexities of the generic drug market and driving innovation in pharmaceutical manufacturing.
Track Record: Under Shingo Iwamoto's leadership, Nichi-Iko Pharmaceutical Co., Ltd. has focused on expanding its generic drug portfolio and strengthening its market position. Key achievements include streamlining manufacturing processes and improving supply chain efficiency. Iwamoto has also emphasized strategic acquisitions to enhance the company's competitive advantage and drive long-term growth.
NHKFF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nichi-Iko Pharmaceutical Co., Ltd. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited regulatory oversight and may not provide regular financial reporting, increasing the risk for investors. Trading on the OTC Other tier typically involves higher risks compared to exchanges like NYSE or NASDAQ due to the lack of stringent listing standards and reporting requirements.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading.
- Less regulatory oversight compared to listed exchanges.
- Potential for fraudulent or manipulative activities.
- Higher risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established history since 1947.
- Focus on manufacturing and distributing pharmaceutical products.
- Presence in the generic drug market.
- Supply relationships with medical institutions.
- Operations through Nichi-Iko Group and Sagent Group.
Nichi-Iko Pharmaceutical Co., Ltd. Healthcare Stock: Key Questions Answered
What does the AI Score mean for NHKFF?
NHKFF holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Nichi-Iko Pharmaceutical Co., Ltd. is a Japanese company focused on manufacturing, selling, and distributing pharmaceutical products, particularly generic drugs. The company operates through two …
What does Nichi-Iko Pharmaceutical Co., Ltd. do?
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes a variety of pharmaceutical products, with a primary focus on generic drugs. Operating through its Nichi-Iko Group and Sagent Group segments, the company supplies medical institutions, including hospitals, clinics, and pharmacies, with treatments for various conditions. These include circulatory, digestive, respiratory, and nervous system disorders, as well as allergies. The company aims to provide affordable healthcare solutions through its generic drug offerings.
What are the main risks for NHKFF?
Nichi-Iko Pharmaceutical Co., Ltd. faces several risks, including intense competition in the generic drug market, which can lead to pricing pressures and reduced profitability. Regulatory challenges and compliance requirements can increase operational costs and delay product approvals. Supply chain disruptions can impact manufacturing and distribution. Additionally, the company's modest profit margin of 3.9% indicates potential operational inefficiencies.
How does Nichi-Iko Pharmaceutical Co., Ltd. navigate regulatory approval processes?
Given the lack of specific information on Nichi-Iko Pharmaceutical Co., Ltd.'s FDA/EMA regulatory track record, pending approvals, and compliance strategy, it is challenging to provide a detailed answer. However, generic drug manufacturers typically navigate regulatory approval processes by demonstrating bioequivalence to branded drugs, adhering to strict manufacturing standards, and complying with labeling requirements.
What is Nichi-Iko Pharmaceutical Co., Ltd.'s drug pipeline status?
Specific details regarding Nichi-Iko Pharmaceutical Co., Ltd.'s drug pipeline status are unavailable. However, generic drug companies typically focus on developing and launching generic versions of existing drugs as their patents expire. This involves demonstrating bioequivalence to the original branded drug and obtaining regulatory approval. Investors should seek information on the company's R&D activities and regulatory filings to assess its pipeline status and potential future growth.
What are the key factors to evaluate for NHKFF?
Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) holds an AI score of 38/100 (low). presents a mixed investment case. Not financial advice.
How frequently does NHKFF data refresh on this page?
NHKFF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NHKFF's recent stock price performance?
Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the generic drug market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NHKFF overvalued or undervalued right now?
Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC disclosure status.
- AI analysis pending for NHKFF.